Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 10, 2020

View Archived Issues

Gracell begins study of GC-027 for relapsed or refractory T-cell malignancies

PERKing up astrocytes fights prion neurodegeneration

First-in-human data presented for BCMA-CD19 cCAR T-cells

Human CD83 CAR T cells for the prevention of GvHD and treatment of AML

Positive 6-month data from ongoing phase I/II study in X-linked retinitis pigmentosa

Regeneron announces phase II data for garetosmab in fibrodysplasia ossificans progressiva

Phase III CONSTANT trial of Sci-B-Vac meets primary and secondary endpoints

Locus begins phase Ib trial of CRISPR Cas3-enhanced bacteriophage product LBP-EC01

Novartis patents new compounds for leishmaniasis and trypanosomiasis

Dana-Farber Cancer Institute discloses new EGFR inhibitors

Aduro BioTech identifies cGAS inhibitors

Drexel University synthesizes new HIV capsid assembly inhibitors

Heptares Therapeutics discovers muscarinic M1 and/or M4 receptor agonists

Inhibrx initiates phase I study of hexavalent OX40 agonist INBRX-106 for solid tumors

Redx Pharma nominates ROCK2 inhibitor RXC-007 as drug development candidate in fibrosis

Biallelic loss-of-function variants in NADSYN1 cause congenital NAD deficiency and malformations

CBX-12 announced as Cybrexa Therapeutics' lead development program

Entrada announces development of ENTR-501 for mitochondrial neurogastrointestinal encephalomyopathy

Transgenic CD2-Lmo2/Ldb1 knockout mouse model of T-ALL

ELP5 found to be involved in gemcitabine sensitivity in gallbladder cancer

Sellas opens enrollment in phase III trial of galinpepimut-S for AML

Aclaris reports phase I data on oral MK2 inhibitor ATI-450

FDA approves Ayvakit for unresectable or metastatic PDGFRA exon 18 mutant GIST

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...